Idiopathic multicentric Castleman disease: bringing order to chaos
Publication date: Available online 3 February 2020Source: The Lancet HaematologyAuthor(s): Heather A Leitch (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 4, 2020 Category: Hematology Source Type: research
Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials
This study was done to assess the long-term safety and activity of siltuximab over up to 6 years of treatment.MethodsThis study is a prespecified open-label extension analysis of a phase 1 trial (NCT00412321) and a phase 2 trial (NCT01024036), done at 26 hospitals worldwide. Patients in both studies were at least 18 years old with histologically confirmed, symptomatic Castleman disease. This extension study enrolled 60 patients who completed the previous trials without disease progression on siltuximab. Patients received siltuximab infusions of 11 mg/kg every 3 weeks (which could be extended to 6 weeks) for up to 6 years. ...
Source: The Lancet Haematology - February 4, 2020 Category: Hematology Source Type: research
Interferon-α: alternative first- or second-line therapeutic option for polycythaemia vera
Publication date: Available online 31 January 2020Source: The Lancet HaematologyAuthor(s): John Mascarenhas (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 1, 2020 Category: Hematology Source Type: research
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
We present the final results of PROUD-PV and an interim analysis at 36 months of the CONTINUATION-PV study (per statistical analysis plan). Analyses for safety and efficacy were per-protocol. The trials were registered on EudraCT, 2012-005259-18 (PROUD-PV) and 2014-001357-17 (CONTINUATION-PV, which is ongoing).FindingsPatients were recruited from Sept 17, 2013 to March 13, 2015 with 306 enrolled. 257 patients were randomly assigned, 127 were treated in each group (three patients withdrew consent in the hydroxyurea group), and 171 rolled over to the CONTINUATION-PV trial. Median follow-up was 182·1 weeks (IQR 166·3–201...
Source: The Lancet Haematology - February 1, 2020 Category: Hematology Source Type: research
Correction to Lancet Haematol 2020; 7: e100–11
Publication date: Available online 29 January 2020Source: The Lancet HaematologyAuthor(s): (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 30, 2020 Category: Hematology Source Type: research
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Publication date: February 2020Source: The Lancet Haematology, Volume 7, Issue 2Author(s): Olaf Penack, Monia Marchetti, Tapani Ruutu, Mahmoud Aljurf, Andrea Bacigalupo, Francesca Bonifazi, Fabio Ciceri, Jan Cornelissen, Ram Malladi, Rafael F Duarte, Sebastian Giebel, Hildegard Greinix, Ernst Holler, Anita Lawitschka, Stephan Mielke, Mohamad Mohty, Mutlu Arat, Arnon Nagler, Jakob Passweg, Hélène SchoemansSummaryGraft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity after allogeneic stem-cell transplantation. Because of the small number of results from well designed, large-scale, clinic...
Source: The Lancet Haematology - January 29, 2020 Category: Hematology Source Type: research
Childhood cancer: the need to invest in the future
Publication date: February 2020Source: The Lancet Haematology, Volume 7, Issue 2Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 29, 2020 Category: Hematology Source Type: research
The demand and supply of blood in India
Publication date: February 2020Source: The Lancet Haematology, Volume 7, Issue 2Author(s): Joy John Mammen, Edwin Sam Asirvatham (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 29, 2020 Category: Hematology Source Type: research
Caution: PET-CT in plasma cell disorders
Publication date: February 2020Source: The Lancet Haematology, Volume 7, Issue 2Author(s): Deepesh P Lad (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 29, 2020 Category: Hematology Source Type: research
Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations
Publication date: February 2020Source: The Lancet Haematology, Volume 7, Issue 2Author(s): Francesco Paolo Tambaro, William G WierdaSummaryTumour lysis syndrome is a complication of chemotherapy for haematological malignancies; in particular, aggressive leukaemias and lymphomas. For haematological malignancies, targeted therapies, such as small molecule inhibitors and monoclonal antibodies, have a high anti-tumour activity, are well tolerated, and have a low incidence of associated tumour lysis syndrome. The BCL-2 inhibitor venetoclax has a high anti-tumour activity in chronic lymphocytic leukaemia, achieving deep remissio...
Source: The Lancet Haematology - January 29, 2020 Category: Hematology Source Type: research
Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now?
Publication date: Available online 23 January 2020Source: The Lancet HaematologyAuthor(s): Jerry L Spivak (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 25, 2020 Category: Hematology Source Type: research
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
This study is registered with ClinicalTrials.gov, NCT01243944.FindingsWe enrolled patients between Oct 27, 2010, and Feb 13, 2013, and the study concluded on Feb 9, 2018. Of 342 individuals screened for eligibility, 222 patients were randomly assigned to receive ruxolitinib (n=110, 50%) or best available therapy (n=112, 50%). The median time since polycythaemia vera diagnosis was 8·2 years (IQR 3·9–12·3) in the ruxolitinib group and 9·3 years (4·9–13·8) in the best available therapy group. 98 (88%) of 112 patients initially randomly assigned to best available therapy crossed over to receive ruxolitinib and no pat...
Source: The Lancet Haematology - January 25, 2020 Category: Hematology Source Type: research
First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an “operational cure”
Publication date: Available online 21 January 2020Source: The Lancet HaematologyAuthor(s): Massimo Breccia, Robin Foà (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 22, 2020 Category: Hematology Source Type: research
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial
This study closed early due to accrual and is registered with the UMIN Clinical Trials Registry (UMIN000011099).FindingsBetween Sept 20, 2013 and July 12, 2016, 68 patients who had a deep molecular response after receiving first-line dasatinib for at least 24 months were enrolled and assigned to the consolidation phase. Nine patients were excluded during the consolidation phase and one patient was excluded after study completion because of meeting exclusion criteria. 58 patients discontinued dasatinib and were assessed. 32 (55%) of 58 patients had treatment-free remission at 6 months after dasatinib discontinuation, and me...
Source: The Lancet Haematology - January 22, 2020 Category: Hematology Source Type: research
Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial
Publication date: Available online 17 January 2020Source: The Lancet HaematologyAuthor(s): Irwin Walker, Tony Panzarella, Stephen Couban, Felix Couture, Gerald Devins, Mohamed Elemary, Geneviève Gallagher, Holly Kerr, John Kuruvilla, Stephanie J Lee, John Moore, Thomas Nevill, Gizelle Popradi, Jean Roy, Kirk R Schultz, David Szwajcer, Cynthia Toze, Ronan Foley, Cell Therapy Transplant CanadaSummaryBackgroundPrevious trials testing prevention strategies for chronic graft versus host disease (GVHD) have measured its cumulative incidence. In this trial of anti-thymocyte globulin, we measured treatment-independence at a long-...
Source: The Lancet Haematology - January 18, 2020 Category: Hematology Source Type: research
